Histone deacetylase inhibitors: discovery and development as anticancer agents

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Histone deacetylase (HDAC) inhibitors represent a novel class of targeted anticancer therapies.
• HDAC inhibitors are demonstrating significant efficacy in clinical trials for both hematological and solid tumors.
• These agents are generally well-tolerated by patients at therapeutic doses.

Purpose of the Study:

• To explore the mechanism of action of HDAC inhibitors in cancer treatment.
• To highlight the selective toxicity of HDAC inhibitors towards cancer cells.
• To underscore the potential of HDAC inhibitors as a therapeutic strategy.

Main Methods:

• Review of current clinical trial data and preclinical studies on HDAC inhibitors.
• Analysis of the molecular mechanisms involving histone and non-histone protein acetylation.
• Examination of gene expression modulation by HDAC inhibitors.

Main Results:

• HDAC inhibitors alter gene expression by modifying histone and transcription factor complexes.
• These agents induce apoptosis selectively in cancer cells.
• Normal cells exhibit relative resistance to HDAC inhibitor-induced cell death.

Conclusions:

• HDAC inhibitors are a promising class of targeted anticancer drugs with a favorable safety profile.
• Their ability to selectively induce cancer cell death warrants further investigation and clinical development.
• HDAC inhibitors offer a targeted approach to cancer therapy by modulating epigenetic regulation.